NYSEAMERICAN:CRMDCorMedix Stock Price, Forecast & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CorMedix.

CorMedix is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for CorMedix.

CorMedix Inc. (NYSEAMERICAN:CRMD) posted its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.24) by $0.10.
View CorMedix's earnings history.

CorMedix shares reverse split on the morning of Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split.

2 brokers have issued 1-year price objectives for CorMedix's stock. Their forecasts range from $10.00 to $12.00. On average, they expect CorMedix's stock price to reach $11.00 in the next year. This suggests a possible upside of 177.8% from the stock's current price.
View analysts' price targets for CorMedix.

Press coverage about CRMD stock has been trending positive on Friday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. CorMedix earned a news sentiment score of 2.7 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
View the latest news about CorMedix.

CorMedix saw a decline in short interest during the month of May. As of May 29th, there was short interest totaling 3,000,000 shares, a decline of 16.9% from the May 14th total of 3,610,000 shares. Based on an average daily volume of 256,500 shares, the days-to-cover ratio is currently 11.7 days.
View CorMedix's Short Interest.

Some companies that are related to CorMedix include Pfenex (PFNX), Neptune Wellness Solutions (NEPT), IMV (IMV), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Synairgen (SNG), Ibio (IBIO), ProMetic Life Sciences (PLI), Fennec Pharmaceuticals (FRX), Verona Pharma (VRP), Ergomed (ERGO), Rafael (RFL), IMV (IMV) and Tiziana Life Sciences (TILS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include ZIOPHARM Oncology (ZIOP), Rexahn Pharmaceuticals (REXN), Amarin (AMRN), Precigen (PGEN), AcelRx Pharmaceuticals (ACRX), Kindred Biosciences (KIN), Sorrento Therapeutics (SRNE), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ) and Agile Therapeutics (AGRX).

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

CorMedix's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Steward Partners Investment Advisory LLC (0.31%), California Public Employees Retirement System (0.20%), Planning Directions Inc. (0.19%), Riversedge Advisors LLC (0.05%), SG Americas Securities LLC (0.05%) and State Board of Administration of Florida Retirement System (0.04%). Company insiders that own CorMedix stock include Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook and Steven W Lefkowitz.
View institutional ownership trends for CorMedix.

CRMD stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for CorMedix.

CRMD stock was purchased by a variety of institutional investors in the last quarter, including Planning Directions Inc., California Public Employees Retirement System, SG Americas Securities LLC, State Board of Administration of Florida Retirement System, Avestar Capital LLC, Steward Partners Investment Advisory LLC, and Riversedge Advisors LLC. Company insiders that have bought CorMedix stock in the last two years include Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook, and Steven W Lefkowitz.
View insider buying and selling activity for CorMedix.

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRMD stock can currently be purchased for approximately $3.96.

CorMedix has a market capitalization of $123.71 million. CorMedix employs 22 workers across the globe.

The official website for CorMedix is www.cormedix.com.

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.